Search
for

    Did you mean Anagen Alopecia?
    GlossaryAnagen Alopecia

    hair loss during the active growth phase

    Anagen Alopecia refers to hair loss that occurs during the anagen phase of the hair growth cycle, which is the active growth phase. This type of alopecia is often caused by factors that disrupt the hair follicle's ability to produce hair, such as chemotherapy or radiation therapy, leading to rapid and widespread hair loss.

    Related Terms

    Learn

    5 / 11 results

      learn Valproic acid

      an anticonvulsant repurposed for hair loss via histone inhibition

      learn Exosomes

      Microscopic delivery system that sends growth-promoting signals to hair follicles

      learn Dexpanthenol

      precursor of vitamin B5 with hair stimulating effects

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

    Research

    5 / 1000+ results

    Community Join

    5 / 67 results

      community 5 Month Dutasteride Progress Before and After

      in Progress Pictures  173 upvotes 2 years ago
      A user experiencing significant hair loss started using Dutasteride, a drug typically used for prostate issues, and noticed a positive change in hair thickness and volume after 5 months. Other users in the conversation also shared their experiences and observations with Dutasteride, with one mentioning additional use of oral Minoxidil.

      community Stop expecting results in 2 months!

      in Treatment  125 upvotes 1 year ago
      People discussing hair loss treatments emphasize the need for patience, as results from using finasteride and minoxidil can take 8-12 months or longer. Some users report early signs of improvement, while others experience continued shedding or slower progress.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.